XB2

Mavacamten

Created:2023-10-26
Last modified:  2025-11-04

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count39
Chiral Atom Count1
Bond Count40
Aromatic Bond Count6
2D diagram of XB2
Toggle HydrogenToggle Labels

Chemical Component Summary

NameMavacamten
Synonyms6-[[(1~{S})-1-phenylethyl]amino]-3-propan-2-yl-1~{H}-pyrimidine-2,4-dione
Systematic Name (OpenEye OEToolkits)6-[[(1~{S})-1-phenylethyl]amino]-3-propan-2-yl-1~{H}-pyrimidine-2,4-dione
FormulaC15 H19 N3 O2
Molecular Weight273.33
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESCACTVS3.385CC(C)N1C(=O)NC(=CC1=O)N[CH](C)c2ccccc2
SMILESOpenEye OEToolkits2.0.7CC(C)N1C(=O)C=C(NC1=O)NC(C)c2ccccc2
Canonical SMILESCACTVS3.385 CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2
Canonical SMILESOpenEye OEToolkits2.0.7 C[C@@H](c1ccccc1)NC2=CC(=O)N(C(=O)N2)C(C)C
InChIInChI1.06 InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
InChIKeyInChI1.06 RLCLASQCAPXVLM-NSHDSACASA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB14921 
NameMavacamten
Groups
  • approved
  • investigational
DescriptionMavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans.[A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471]
Synonyms
  • Mavacamten
  • MYK-461
  • 6-(((1S)-1-Phenylethyl)amino)-3-(propan-2-yl)-1,2,3,4 tetrahydropyrimidine-2,4-dione
Brand NamesCamzyos
IndicationMavacamten is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms by the FDA, Health Canada, and the EMA.[L41680,L44106,L47466]
Categories
  • Amines
  • Benzene Derivatives
  • Benzyl Compounds
  • Cardiac Myosin Inhibitor
  • Cardiac Therapy
ATC-CodeC01EB24
CAS number1642288-47-8

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Myosin-7MGDSEMAVFGAAAPYLRKSEKERLEAQTRPFDLKKDVFVPDDKQEFVKAK...unknowninhibitory allosteric modulator
Cytochrome P450 2C8MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...unknownsubstrate
Cytochrome P450 3A5MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...unknownsubstrate
Cytochrome P450 2C9MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...unknownsubstrate,inducer
Cytochrome P450 2C19MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDV...unknownsubstrate,inducer
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL4297517
PubChem 117761397
ChEMBL CHEMBL4297517